Short-course versus long-course chemoradiation in rectal cancer--time to change strategies?

Published

Journal Article (Review)

OPINION STATEMENT: There is significant debate regarding the optimal neoadjuvant regimen for resectable rectal cancer patients. Short-course radiotherapy, a standard approach throughout most of northern Europe, is generally defined as 25 Gy in 5 fractions over the course of 1 week without the concurrent administration of chemotherapy. Long-course radiotherapy is typically defined as 45 to 50.4 Gy in 25-28 fractions with the administration of concurrent 5-fluoropyrimidine-based chemotherapy and is the standard approach in other parts of Europe and the United States. At present, two randomized trials have compared outcomes for short course radiotherapy with long-course chemoradiation showing no difference in respective study endpoints. Late toxicity data are lacking given limited follow-up. Although the ideal neoadjuvant regimen is controversial, our current bias is long-course chemoradiation to treat patients with locally advanced, resectable rectal cancer.

Full Text

Duke Authors

Cited Authors

  • Palta, M; Willett, CG; Czito, BG

Published Date

  • September 2014

Published In

Volume / Issue

  • 15 / 3

Start / End Page

  • 421 - 428

PubMed ID

  • 24915746

Pubmed Central ID

  • 24915746

Electronic International Standard Serial Number (EISSN)

  • 1534-6277

Digital Object Identifier (DOI)

  • 10.1007/s11864-014-0296-2

Language

  • eng

Conference Location

  • United States